Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.22.4
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue $ 509,728 $ 484,329 $ 444,448
Clinical Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue 418,754 404,172 382,337
Pharma Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue 90,974 80,157 62,111
Client direct billing | Clinical Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue 279,732 252,617 240,535
Commercial insurance | Clinical Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue 73,280 78,773 76,550
Medicare and other government | Clinical Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue 65,585 72,010 64,776
Self-pay | Clinical Services      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total net revenue $ 157 $ 772 $ 476